Caribou Biosciences (CRBU) Total Current Liabilities (2020 - 2026)
Caribou Biosciences (CRBU) posted quarterly Total Current Liabilities of $19.7 million for Q1 2026, down 30.95% year-over-year from $28.5 million in Q1 2025, and down 22.59% quarter-over-quarter from $25.4 million in Q4 2025.
Caribou Biosciences (CRBU) Total Current Liabilities (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has reported Total Current Liabilities for 7 consecutive years, with $19.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities fell 30.95% year-over-year to $19.7 million; the TTM figure through Mar 2026 stood at $19.7 million (down 30.95% YoY), while the FY2025 annual figure was $25.4 million, down 17.09% from the prior year.
- Total Current Liabilities fell to $19.7 million in Q1 2026 per CRBU's latest filing, from $25.4 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $34.4 million in Q2 2023 and bottomed at $19.7 million in Q1 2026.
- Historically, Total Current Liabilities has averaged $28.2 million across 5 years, with a median of $28.5 million in 2025.
- Annual changes were most pronounced in 2024 — Total Current Liabilities surged 30.88% — and 2026, when it plunged 30.95%.
- Caribou Biosciences' Total Current Liabilities stood at $28.1 million in 2022, then increased by 0.62% to $28.3 million in 2023, then rose by 8.3% to $30.7 million in 2024, then decreased by 17.09% to $25.4 million in 2025, then slipped by 22.59% to $19.7 million in 2026.
- Business Quant data shows CRBU's Total Current Liabilities at $19.7 million in Q1 2026, $25.4 million in Q4 2025, and $28.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.59 Bn | 131.73 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.21 Bn | 78.22 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.65 Bn | 60.47 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 630.93 Mn |
| 10 | Caribou Biosciences | 167.65 Mn | 55.33 Mn | - | 17.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.97 Mn |
| Mar 31, 2026 | 19.67 Mn |
| Dec 31, 2025 | 25.41 Mn |
| Sep 30, 2025 | 28.06 Mn |
| Jun 30, 2025 | 28.89 Mn |
| Mar 31, 2025 | 28.49 Mn |
| Dec 31, 2024 | 30.65 Mn |
| Sep 30, 2024 | 32.16 Mn |
| Jun 30, 2024 | 30.94 Mn |
| Mar 31, 2024 | 29.02 Mn |
| Dec 31, 2023 | 28.30 Mn |
| Sep 30, 2023 | 24.57 Mn |
| Jun 30, 2023 | 34.38 Mn |
| Mar 31, 2023 | 27.10 Mn |
| Dec 31, 2022 | 28.13 Mn |
| Sep 30, 2022 | 28.81 Mn |
| Jun 30, 2022 | 28.86 Mn |
| Mar 31, 2022 | 26.67 Mn |
| Dec 31, 2021 | 25.83 Mn |
| Sep 30, 2021 | 26.16 Mn |